SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-251515"
 

Search: onr:"swepub:oai:DiVA.org:uu-251515" > EGFR-expression in ...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Carlsson, JörgenUppsala universitet,Medicinsk strålningsvetenskap (author)

EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides

  • Article/chapterEnglish2015

Publisher, publication year, extent ...

  • 2015-03-03
  • Walter de Gruyter GmbH,2015
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-251515
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-251515URI
  • https://doi.org/10.2478/raon-2014-0015DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:130880383URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background. There is limited effect of tyrosine kinase inhibitors or "naked" antibodies binding EGFR or HER2 for therapy of metastasized urinary bladder canter and these methods are therefore not routinely used. Targeting radionuclides to the extracellular domain of the receptors is potentially a better possibility. Methods. EGFR- and HER2-expression was analyzed for primary tumors and corresponding metastases from 72 patients using immunohistochemistry and the internationally recommended HercepTest. Intracellular mutations were not analyzed since only the receptors were considered as targets and intracellular abnormalities should have minor effect on radiation dose. Results. EGFR was positive in 71% of the primary tumors and 69% of corresponding metastases. Local and distant metastases were EGFR-positive in 75% and 66% of the cases, respectively. The expression frequency of HER2 in related lesions was slightly higher (data from previous study). The EGFR-positive tumors expressed EGFR in metastases in 86% of the cases. The co-expression of EGFR and HER2 was 57% for tumors and 53% for metastases. Only 3% and 10% of the lesions were negative for both receptors in tumors and metastases, respectively. Thus, targeting these receptors with radionuclides might be applied for most patients. Conclusions. At least one of the EGFR- or HER2-receptors was present in most cases and co-expressed in more than half the cases. It is therefore interesting to deliver radionuclides for whole-body receptor-analysis, dosimetry and therapy. This can hopefully compensate for resistance to other therapies and more patients can hopefully be treated with curative instead of palliative intention.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Wester, KennethUppsala universitet,Institutionen för immunologi, genetik och patologi(Swepub:uu)kennwest (author)
  • De La Torre, ManuelUppsala universitet,Molekylär och morfologisk patologi(Swepub:uu)manutorr (author)
  • Malmström, Per-UnoUppsala universitet,Urologkirurgi(Swepub:uu)perunoms (author)
  • Gardmark, TrulsKarolinska Institutet (author)
  • Uppsala universitetMedicinsk strålningsvetenskap (creator_code:org_t)

Related titles

  • In:Radiology and Oncology: Walter de Gruyter GmbH49:1, s. 50-581318-20991581-3207

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view